Format

Send to

Choose Destination
Breast Cancer Res. 2012 Jun 19;14(3):209.

Targeted therapies in breast cancer: are heart and vessels also being targeted?

Author information

1
Department of Medical Oncology, Jules Bordet Institute, Université Libre de Bruxelles, 1000 Brussels, Belgium. joelle.masina@bordet.be

Abstract

The concept of 'targeted' therapies implies that such drugs only act on cells that specifically express the particular target, therefore giving rise to a low incidence of side effects. However, targeted therapies currently approved for the treatment of breast cancer have demonstrated a relatively high incidence of cardiovascular events. The anti-HER2 agents trastuzumab and lapatinib may cause left ventricular dysfunction or even congestive heart failure. Bevacizumab, an antiangiogenic drug, has been shown to increase the risk of hypertension, cardiovascular dysfunction and thromboembolic events. In addition, several anti-human epidermal growth factor receptor 2 (HER2) and antiangiogenic agents plus their combinations are currently being developed and evaluated for the treatment of breast cancer. In this review, we aim to assess the incidence of cardiac adverse events associated with targeted therapies designed to block HER2 and angiogenic pathways.

PMID:
22713170
PMCID:
PMC3446327
DOI:
10.1186/bcr3142
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center